Citations

Showing 10 of 108135 citations.

Commentary: Surgical Treatment of Intraneural Ganglion Cysts of the Ulnar Nerve at the Elbow: Long-Term Follow-up of 9 Cases
Spinner, Robert J. , Desy, Nicholas M. , Amrami, Kimberly K. , Simon, Neil G.

Mayo Clinic

Neurosurgery | May 20, 2019 | Volume: 85 | Issue: 6 | Pages: E1076-E1077

10.1093/neuros/nyz242 | PMID 31245807 Get It

Reply: P300 amplitudes after concussions are usually decreased not increased
Fickling, Shaun D. , Smith, Aynsley M., Hajra, Sujoy Ghosh , Liu, Careesa C. , D’Arcy, Ryan C.N., Farrell, Kyle , Farrell, Kyle J , Song, Xiaowei , Stuart, Michael J. , D’Arcy, Ryan C.N.

Mayo Clinic

Brain | May 20, 2019 | Volume: 142 | Issue: 7 | Pages: e33-e33

10.1093/brain/awz147 | PMID 31203375 Get It

Spatio-temporal comparison of pertussis outbreaks in Olmsted County, Minnesota, 2004–2005 and 2012: a population-based study
Wheeler, Philip H., Kaur, Harsheen, Ryu, Euijung , Juhn, Young J. , Juhn, Young, Wi, Chung‐Il , Kim, Dohyeong

Mayo Clinic

BMJ Open | May 20, 2019 | Volume: 9 | Issue: 5 | Pages: e025521

10.1136/bmjopen-2018-025521 | PMID 31110089 Get It

Objective Two pertussis outbreaks occurred in Olmsted County, Minnesota, during 2004–2005 and 2012 (5–10 times higher than other years), with significantly higher incidence than for the State. We aimed to assess whether there were similar spatio-temporal patterns between the two outbreaks. Setting Olmsted County, Minnesota, USA Participants We conducted a population-based retrospective cohort study of all Olmsted County residents during the 2004–2005 and 2012 outbreaks, including laboratory-positive pertussis cases. Primary outcome measure For each outbreak, we estimated (1) age-specific incidence rate using laboratory-positive pertussis cases (numerator) and the Rochester Epidemiology Project Census (denominator), a medical record-linkage system for virtually all Olmsted County residents, and (2) pertussis case density using kernel density estimation to identify areas with high case density. To account for population size, we calculated relative difference of observed density and expected density based on age-specific incidence. Results We identified 157 and 195 geocoded cases in 2004–2005 and 2012, respectively. Incidence was the highest among adolescents (ages 11 to <14 years) for both outbreaks (9.6 and 7.9 per 1000). The 2004–2005 pertussis outbreak had higher incidence in winter (52% of cases) versus summer in 2012 (53%). We identified a consistent area with higher incidence at the beginning (ie, first quartile) of two outbreaks, but it was inconsistent for later quartiles. The relative difference maps for the two outbreaks suggest a greater role of neighbourhood population size in 2012 compared with 2004–2005. Conclusions Comparing spatio-temporal patterns between two pertussis outbreaks identified a consistent geographical area with higher incidence of pertussis at the beginning of outbreaks in this community. This finding can be tested in future outbreaks, and, if confirmed, can be used for identifying epidemiological risk factors clustered in such areas for geographically targeted intervention.
Midterm outcomes of 146 EVOLVE Proline modular radial head prostheses: a systematic review
Laumonerie, Pierre , Raad, Maroun , Tibbo, Meagan E. , Kerezoudis, Panagiotis , Bonnevialle, Nicolas , Mansat, Pierre , Laumonerie, Pierre

Mayo Clinic

Shoulder & Elbow | May 20, 2019 | Volume: 13 | Issue: 2 | Pages: 205-212

10.1177/1758573219850111 | PMID 33897852 Get It

Introduction The EVOLVE implant (Wright Medical Technology, Arlington, TN, USA) is a modular loose-fitting radial head prosthesis. The primary objective was to synthesize all available literature investigating the midterm clinical outcomes of the EVOLVE implant. Materials and methods An electronic literature search in Pubmed/Medline, Scopus, EMBASE, and Cochrane library was performed querying for studies published in 2000–2017. Articles describing clinical and radiographical outcomes as well as reoperation were included. Outcomes of interest included range of motion, Mayo Elbow Performance Score, Disabilities of the Arm Shoulder and Hand, radiographic outcome, and reason for reoperation. Results A total of five articles consisting of 146 patients with EVOLVE implants were included. Mean patient age was 57.4 years (range 22–84), and 43.8% were males (n = 64). Mean follow-up was 4.8 years (range 1–14). Mean Mayo Elbow Performance Score and Disabilities of the Arm Shoulder and Hand score were 87.6 (range 30–100) and 18.9 (range 0–82), respectively. Midterm clinical results were good or excellent (Mayo Elbow Performance Score > 74) in 94 patients. Reoperation was observed in 12 patients, with implant revision required in 2 patients. The primary reason for reoperation was persistent stiffness (n = 9). Conclusion Midterm outcomes of EVOLVE radial head prosthesis are satisfactory, and associated complication rates are low. Loose-fit implant method appears to be a reliable approach to avoid failure of radial head prosthesis by painful loosening.
The association of resistance training with mortality: A systematic review and meta-analysis
Saeidifard, Farzane , Medina‐Inojosa, José R. , Olson, Thomas P. , Bonikowske, Amanda R. , Vinciguerra, Manlio , Vinciguerra, Manlio , Medina-Inojosa, José R , Bonikowske, Amanda , West, Colin P. , Somers, Virend K. , Prokop, Larry J. , López-Jiménez, Francisco

Mayo Clinic

European Journal of Preventive Cardiology | May 20, 2019 | Volume: 26 | Issue: 15 | Pages: 1647-1665

10.1177/2047487319850718 | PMID 31104484 Get It

Background The benefits of aerobic exercise are well-studied; there is no consensus on the association between resistance training and major adverse cardiovascular outcomes. This systematic review and meta-analysis aimed to address this issue. Design and methods We searched for randomized trials and cohort studies that evaluated the association between resistance training and mortality and cardiovascular events. Two investigators screened the identified abstracts and full-texts independently and in duplicate. Cochrane tools were used to assess the risk of bias. We calculated hazard ratios and 95% confidence intervals using random effect models. Results From the 1430 studies identified, 11 (one randomized trial and 10 cohort studies) met the inclusion criteria, totaling 370,256 participants with mean follow-up of 8.85 years. The meta-analysis showed that, compared with no exercise, resistance training was associated with 21% (hazard ratio (95% confidence interval (CI)), 0.79 (0.69–0.91)) and 40% (hazard ratio (95% CI), 0.60 (0.49–0.72)) lower all-cause mortality alone and when combined with aerobic exercise, respectively. Furthermore, resistance training had a borderline association with lower cardiovascular mortality (hazard ratio (95% CI), 0.83 (0.67–1.03)). In addition, resistance training showed no significant association with cancer mortality. Risk of bias was low to intermediate in the included studies. One cohort study looked at the effect of resistance training on coronary heart disease events in men and found a 23% risk reduction (risk ratio, 0.77, CI: 0.61–0.98). Conclusion Resistance training is associated with lower mortality and appears to have an additive effect when combined with aerobic exercise. There are insufficient data to determine the potential beneficial effect of resistance training on non-fatal events or the effect of substituting aerobic exercise with resistance training.
A new instrument for predicting survival of patients with cerebral metastases from breast cancer developed in a homogeneously treated cohort
Hansen, Heinke C., Dziggel, Liesa, Rades, Dirk , Schild, Steven E. , Janssen, Stefan

Mayo Clinic

Radiology and Oncology | May 19, 2019 | Volume: 53 | Issue: 2 | Pages: 219-224

10.2478/raon-2019-0020 | PMID 31103998 Get It

Abstract Background Previous survival scores for breast cancer patients with cerebral metastases were developed in cohorts receiving heterogeneous treatments, which could have introduced selection biases. A new instrument (WBRT-30-BC) was created from 170 patients receiving whole-brain radiotherapy (WBRT) alone with 30 Gy in 10 fractions. Methods Characteristics showing significant associations (p < 0.05) with overall survival (OS) or a trend (p < 0.08) on multivariate analysis were used for the WBRT-30-BC. For each characteristic, 6-month OS rates were divided by 10. These scoring points were added for each patient (patient scores). The WBRT-30-BC was compared to the diagnosis- specific graded prognostic assessment (DS-GPA) classification and Rades-Score for breast cancer regarding positive predictive values (PPVs) to identify patients dying within 6 months and patients surviving at least 6 months following WBRT. Results On multivariate analysis, Karnofsky performance score (KPS) was significant (risk ratio [RR]: 2.45, p < 0.001). In addition, extra-cerebral metastatic disease (RR: 1.52, p = 0.071) and time between breast cancer diagnosis and WBRT (RR: 1.37, p = 0.070) showed a trend. Based on these three characteristics, four predictive groups were designed: 7–9, 10–12, 13–15 and 16 points. Six-month OS rates were 8%, 41%, 68% and 100% (p < 0.001). PPVs to identify patients dying within 6 months were 92% (WBRT-30-BC), 84% (DS-GPA) and 92% (Rades-Score). PPVs to identify patients surviving for at least 6 months were 100% (WBRT-30-BC), 74% (DS-GPA) and 68% (Rades-Score). Conclusions The WBRT-30-BC appeared very accurate in predicting death ≤ 6 months and survival ≥ 6 months of breast cancer patients receiving WBRT. It was superior to previous instruments in predicting survival ≥ 6 months.
Cystic Fibrosis–Associated Liver Disease in Lung Transplant Recipients
Mallea, Jorge M. , Bolan, Candice W. , Cortese, Cherise , Harnois, Denise M. , Mallea, Jorge , Bolan, Candice, Harnois, Denise

Mayo Clinic

Liver Transplantation | May 18, 2019 | Volume: 25 | Issue: 8 | Pages: 1265-1275

10.1002/lt.25496 | PMID 31102574 Get It

Cystic fibrosis (CF) is an autosomal recessive disease characterized by mutations in the gene that encodes for the cystic fibrosis transmembrane conductance regulator protein (CFTR). CFTR gene mutations manifest as epithelial cell dysfunction in the airways, biliary tract, pancreas, gut, sweat glands, paranasal sinuses, and genitourinary tract. The clinical manifestations of this dysfunction include respiratory tract infections, bronchiectasis, pancreatic insufficiency, malabsorption, intestinal obstruction, liver disease, and male infertility. The liver disease manifestations of CF can include biliary disease, multilobular cirrhosis, and portal hypertension with and without cirrhosis. Pulmonary disease is the main cause for morbidity and mortality in individuals with CF, and according to the International Society for Heart and Lung Transplantation, CF is the third most common indication for lung transplantation in adults, accounting for 16% of procedures performed. The survival after lung transplantation in individuals with CF continues to improve and is now the highest among end‐stage lung diseases requiring transplant. The survival rate at 10 years is close to 50%. Given the potential presence of liver disease in CF patients undergoing an evaluation for lung transplantation and in lung transplant recipients, it is important to understand the manifestations of liver disease in CF patients and the recommended workup and follow‐up. This review aims to discuss the current literature and provide guidance in the management of these patients.
Prognostic factors in patients treated with transarterial radioembolization for unresectable and chemorefractory colorectal cancer with liver metastases
Jia, Zhongzhi , Paz‐Fumagalli, Ricardo , Frey, G. , Sella, David M., McKinney, J. Mark , Wang, Weiping , Frey, Gregory T

Mayo Clinic

Expert Review of Gastroenterology & Hepatology | May 18, 2019 | Volume: 13 | Issue: 9 | Pages: 899-905

10.1080/17474124.2019.1621166 | PMID 31104533 Get It

Method of levels not limits for assessment of cooling detection thresholds
Dyck, P. James B. , Dyck, Peter J., Dyck, Peter J., Dyck, Peter J., Dyck, Peter J.

Mayo Clinic

Muscle & Nerve | May 18, 2019 | Volume: 60 | Issue: 2 | Pages: 109-110

10.1002/mus.26519 | PMID 31102274 Get It

See article on pages 141–146 in this issue.
Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma
Luchtel, Rebecca A. , Zimmermann, Michael T. , Hu, Guangzhen , Dasari, Surendra , Jiang, Manli, Jacobs, Hailey K., Zeng, Yu , Hundal, Tanya , Lee, Jeong‐Heon , Eckloff, Bruce W., Yan, Huihuang , Gaonkar, Krutika S. , Tian, Shulan , Ye, Zhenqing, Sidhu, Jagmohan S. , Jiang, Liuyan , Voss, Jesse S. , Link, Brian K. , Syrbu, Sergei , Ördög, Tamás , Kocher, Jean‐Pierre , Ansell, Stephen M. , Lee, Jeong-Heon , Jiang, Liuyan , Ordog, Tamas , Cerhan, James R , Feldman, Andrew L , Link, Brian K , Zimmermann, Michael T , Syrbu, Sergei , Oishi, Naoki , Rech, Karen L. , Ketterling, Rhett P. , Kadin, Marshall E. , Facchetti, Fabio , Bennani, N. Nora , Slager, Susan L. , Cerhan, James R. , Feldman, Andrew L.

Mayo Clinic

Blood | May 18, 2019 | Volume: 133 | Issue: 26 | Pages: 2776-2789

10.1182/blood.2019000626 | PMID 31101622 Get It

AbstractAnaplastic large cell lymphomas (ALCLs) represent a relatively common group of T-cell non-Hodgkin lymphomas (T-NHLs) that are unified by similar pathologic features but demonstrate marked genetic heterogeneity. ALCLs are broadly classified as being anaplastic lymphoma kinase (ALK)+ or ALK−, based on the presence or absence of ALK rearrangements. Exome sequencing of 62 T-NHLs identified a previously unreported recurrent mutation in the musculin gene, MSCE116K, exclusively in ALK− ALCLs. Additional sequencing for a total of 238 T-NHLs confirmed the specificity of MSCE116K for ALK− ALCL and further demonstrated that 14 of 15 mutated cases (93%) had coexisting DUSP22 rearrangements. Musculin is a basic helix-loop-helix (bHLH) transcription factor that heterodimerizes with other bHLH proteins to regulate lymphocyte development. The E116K mutation localized to the DNA binding domain of musculin and permitted formation of musculin–bHLH heterodimers but prevented their binding to authentic target sequence. Functional analysis showed MSCE116K acted in a dominant-negative fashion, reversing wild-type musculin-induced repression of MYC and cell cycle inhibition. Chromatin immunoprecipitation–sequencing and transcriptome analysis identified the cell cycle regulatory gene E2F2 as a direct transcriptional target of musculin. MSCE116K reversed E2F2-induced cell cycle arrest and promoted expression of the CD30–IRF4–MYC axis, whereas its expression was reciprocally induced by binding of IRF4 to the MSC promoter. Finally, ALCL cells expressing MSCE116K were preferentially targeted by the BET inhibitor JQ1. These findings identify a novel recurrent MSC mutation as a key driver of the CD30–IRF4–MYC axis and cell cycle progression in a unique subset of ALCLs.